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Abstract 
Objective 
A growing literature indicates that unipolar and bipolar depression are associated with 
alterations in grey matter volume. However, it is unclear to what degree these patterns of 
morphometric change reflect symptom dimensions. Here, we aimed to predict depressive 
symptoms and hypomanic symptoms based on patterns of grey matter volume using machine 
learning. 
Method 
We used machine learning methods combined with voxel-based morphometry to predict 
depressive and self-reported hypomanic symptoms from grey matter volume in a sample of 
47 individuals with un-medicated unipolar and bipolar depression.  
Results 
We were able to predict depressive severity from grey matter volume in the antero-ventral 
bilateral insula in both unipolar and bipolar depression. Self-reported hypomanic symptoms 
did not predict grey matter loss with a significant degree of accuracy.  
Discussion 
The results of this study suggest that patterns of grey matter volume alteration in the insula 
are associated with depressive symptom severity across unipolar and bipolar depression. 
Studies using other modalities, and exploring other brain regions with a larger sample are 
warranted to identify other systems that may be associated with depressive and hypomanic 
symptoms across affective disorders. 
Keywords: Depression, bipolar disorder, magnetic resonance imaging, MRI, Machine 
learning, VBM, DARTEL 
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Significant outcomes 
• Grey matter volume, in regions previously shown to be commonly reduced in unipolar 
and bipolar depression, is associated with depressive symptom severity across these 
disorders. This relationship is most pronounced in the insula. 
• Depressive severity can be predicted accurately at the individual level based on grey 
matter volume 
• Self-reported hypomanic symptom severity was not able to be predicted accurately 
using grey matter volume 
Limitations 
• This study relies on retrospective, self-reported hypomanic symptoms which may be 
inaccurate 
• The number of subjects with bipolar disorder was low relative to the number with 
unipolar depression. 
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Introduction 
Affective disorders such as major depression and bipolar disorder are common disorders with 
profound effects on sufferers and society (1,2). Depressive episodes, often with a recurrent 
pattern, occur in both conditions and are generally considered the most burdensome disease 
contributor leading to substantial functional impairment. Identifying biological signatures of 
clinical symptoms of depression and mood elevation within affective disorders at the earliest 
opportunity is a research priority necessary to aid diagnostic identification and differentiation 
within affective disorders and provide effective treatment with increased specificity (3).  
Recent research has indicated similarities in grey matter volume reduction across the brain 
between unipolar and bipolar disorders (4–7). Notably, we have demonstrated a specific 
pattern of volumetric reduction in the medial prefrontal cortex and insula bilaterally in both 
unipolar and bipolar disorders, which may represent the morphometric substrate of depressive 
symptoms across mood disorders (7). We have also identified a preferential pattern of grey 
matter loss in unipolar major depression compared to bipolar disorder in the left hippocampus, 
right middle temporal gyrus and right dorsolateral prefrontal cortex (7) which might aid clinical 
identification of bipolarity in the presence of a depressed mood state. Early identification of 
bipolarity at the brain level is a research target as diagnostic discrimination can be clinically 
very difficult as  “unipolar” major depressive episodes are commonly the first presentation (8–
10). Furthermore, individuals with a bipolar diathesis, even below the threshold for diagnosis 
with bipolar disorder, are more likely to develop more severe illness trajectories (11), and 
attempt suicide (10). 
However, the networks we identified originated from a large meta-analysis of cross sectional 
studies and remain fundamentally untested in a new sample of people with mood disorders in 
relation to mood state. This is an important next step to precisely define the veracity of this 
pattern of brain abnormalities and their relationship to mood state across psychiatric disorders 
with overlapping clinical characteristics. This is especially relevant for regions like the insula 
known to be involved in a number of psychiatric presentations (12).  
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In this study, we sought to confirm whether our pattern of pre-identified grey matter loss in the 
prefrontal cortex and insula, common to both unipolar and bipolar depression, relate to 
symptoms of major depression in a sample of medication free individuals with mood disorders. 
We attempted to identify an unknown bipolar diathesis, by tentatively evaluating the predictive 
value of variation in grey matter volume in the brain regions shown to differentiate unipolar 
and bipolar disorders in our model (left hippocampus, right middle temporal gyrus and right 
dorsolateral prefrontal cortex). This was a secondary analysis because the study investigated 
depressed individuals in the absence of overt symptoms of mania or hypomania. Hence, we 
expected that alterations in the brain will be less noticeable in the absence of current 
symptoms. For this purpose we employed a self-report measure of hypomanic symptoms,  the 
‘Hypomania Checklist’ in view of its recognised sensitivity in detecting a bipolar diathesis in 
patients presenting with symptoms of unipolar depression (13).  
We measured grey matter volume using voxel-based morphometry (14), which provides an 
effective method of mapping grey matter volume across the brain, providing an effective way 
of identifying localised volumetric changes in clinical groups. In effect, the method provides a 
measure of individual subjects’ grey matter volume in each voxel of a structural image. While 
these images have most commonly been compared between groups using standard statistical 
methods, more recently machine learning techniques have been applied to these measures 
(3). An important feature of these methods is that, rather than simply comparing the value of 
each voxel between groups, they use the pattern of grey matter volume measurements in a 
particular region to either classify diagnostic groups or predict a continuous clinical measure. 
These methods have two major advantages over traditional univariate methods: firstly, their 
multivariate nature allows detection of complex patterns represented across multiple voxels, 
unlike traditional univariate analyses where each voxel is analysed independently, and 
secondly, they allow single-subject prediction, enabling us to identify an individual’s level of 
symptoms based on brain structure. This is of particular relevance to psychiatric disorders 
because it allows more subtle detection of distributed patterns and individual-subject level 
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predictions of clinical status. We performed this study in a sample of medication-free 
individuals experiencing a depressive episode, focusing on current depressive symptoms and 
self-reported historic hypomanic/manic symptoms.  
 
While previous studies have addressed similar questions (15,16), our work is the first to use 
multivariate methods to assess the relationship between volumetric patterns and symptom 
severity, and is also the first to investigate this relationship across unipolar and bipolar 
depression.  
We firstly hypothesised that grey matter volume in regions demonstrating volumetric reduction 
across unipolar and bipolar disorders, including the bilateral insula and medial prefrontal 
cortex, would predict depressive symptom severity irrespective of diagnosis, providing a 
common substrate for depressive symptoms in affective disorders. Secondly, we explored the 
possibility that grey matter volume in regions previously shown to distinguish unipolar and 
bipolar disorders, including the hippocampus and dorsolateral prefrontal cortex, would predict 
self-reported hypomanic symptom severity. 
 
Methods 
Participants 
Participants were recruited from public advertisements (17) and local psychological therapy 
services and underwent a diagnostic interview based on the Mini International 
Neuropsychiatric Interview (18). Subjects were recruited from our research programme 
investigating biological mechanisms underpinning major depression and bipolarity by using 
neuroimaging techniques.  
Patients were assessed by a psychiatrist (DA) and a trained researcher (LM) and met Axis I 
DSM-IV criteria for unipolar major depression or bipolar disorder. Inter-rater reliability for 
depressive symptoms was high (intraclass correlation coefficient = 0.96, p = .004). The 
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diagnosis was further substantiated by review of medical notes and collateral information to 
exclude axis II comorbidity as far as possible. The Young Mania Rating Scale (19) was used 
to exclude current hypomania/mania mixed episodes in bipolar patients. Duration of illness 
was calculated as the number of years since the onset of any mood episode. 
Inclusion criteria were: 1) experiencing a moderate to severe depressive episode at the time 
of inclusion assessed using the Montgomery-Åsberg Depression Rating Scale (MÅDRS, 
Montgomery & Åsberg, 1979) with a score of ≥18; 2) medication-free for ≥2 weeks (≥4 weeks 
for fluoxetine) and not receiving any psychological intervention at the time of scanning, 3) right 
handedness (assessed using the Edinburgh Handedness Scale) (21), and 4) not meeting 
criteria for substance/alcohol misuse disorder (participants were excluded if they reported any 
illicit substance use in the previous two months). Any unstable medical condition, medication 
that could affect safety, study results, analyses or interpretation were excluded. All participants 
were screened for MRI safety. 
Depressive symptom severity was assessed using the MÅDRS, and the total score was used 
in correlational analyses. Historical hypomanic symptoms were assessed using the 33-item 
hypomania checklist (HCL), a self-report measure that has been shown to reliably detect 
symptoms of hypomania (13,22).  The questionnaire features a range of symptoms present 
during “high” states (e.g. “I talk more”, “I need less sleep”) and the overall score is calculated 
as total number of items that the subject endorses. This questionnaire was chosen as it is 
sensitive to variation in hypomanic symptoms and provides a continuous measure of bipolarity 
adjunct to categorical diagnosis. The total scale score was used in correlational analysis in 
this study. 
The research was approved by the relevant local ethics committee and informed consent was 
obtained from each participant. All participants were compensated for taking part in the 
research. 
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Structural imaging 
High resolution T1-weighted structural images were acquired on one of two identical GE 
MR750 3 Tesla scanners at the same site, using identical sequences (TR=7.31ms, 
TE=3.02ms, 256 x 256 matrix, 196 slices, voxel size = 1.2 x 1.05 x 1.05mm). 
Voxel-based morphometry 
Structural images were pre-processed using voxel-based morphometry in SPM12 
(www.fil.ion.ucl.ac.uk/spm). Images were segmented into grey matter, white matter, and 
cerebrospinal fluid and processed with DARTEL (23) before being normalised to MNI space. 
The modulated grey matter images were then smoothed with an 8mm FWHM Gaussian kernel 
and the resulting images were used as input for further analyses. Data were Z-scored prior to 
further machine learning analysis. 
Machine learning 
To identify distributed patterns of grey matter volume alteration that predict depressive and 
hypomanic symptoms, we used support vector regression (24) with a linear kernel 
implemented in the Scikit-learn module for Python (25). This is an extension of the support 
vector machine classification method that aims to predict a continuous target variable, in our 
case symptom severity scores, by finding a linear hyperplane with minimal distance from the 
observed data points, subject to penalisation of residuals greater than ε by constant C to limit 
overfitting. This can be used to predict target values associated with previously unseen data. 
Predictive accuracy was assessed using leave-one-out cross validation. This involves training 
the model on all but one of the observations and testing its predictive accuracy on the withheld 
sample, repeating this process for every possible combination of training and testing data. We 
assessed the statistical significance of the results using permutation testing with 1000 
permutations, whereby the model was repeatedly evaluated on data with target MÅDRS or 
HCL scores randomly reshuffled to provide an empirically derived null distribution which is 
used to determine the probability of the observed predictive accuracy occurring under the null 
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hypothesis. The value of parameters C and ε were set using random search (26). Prediction 
accuracy was quantified using mean-squared error (MSE), however we also report mean 
absolute error for ease of interpretation. 
Reducing the dimensionality of input data, a process known as feature selection, is crucial to 
ensure accurate predictions when using machine learning methods (27). We focused on brain 
regions shown to either differentiate unipolar from bipolar disorder, or be commonly affected 
in both disorders, based on our previous meta-analysis (7). Regions differentiating the two 
disorders included left hippocampus, right middle temporal gyrus, right middle frontal gyrus, 
cerebellar vermis, and left inferior parietal lobule (7), and these were used to create a region 
of interest mask that was used to predict hypomanic symptoms. The regions common to the 
two disorders included the ventromedial prefrontal cortex, anterior cingulate cortex, and insula, 
and these areas were used to predict depressive symptom severity in the present study. Thus 
feature selection was based on independent data and does not result in “double dipping” (27). 
Feature weights from the support vector regression were extracted and plotted to identify the 
voxels contributing most highly to the prediction.  
Univariate analyses 
To compare the performance of the support vector regression model in detecting regions of 
grey matter variation predicting depressive and hypomanic symptoms against traditional 
univariate methods, linear regression analyses in SPM were used to identify regions of grey 
matter alteration that correlated with MÅDRS and HCL scores, covarying for intracranial 
volume and scanner. As with the support vector regression, statistical analyses used a region 
of interest approach, focusing on regions identified in our previous meta-analysis (7). 
Statistical maps were thresholded with a voxelwise threshold of < .001 uncorrected and a 
cluster-wise significance threshold of < .05 FDR corrected. 
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Unipolar 
Depression 
Bipolar 
Depression 
p 
N 39 BP-I = 2; BP-II = 6 NA 
Age, years 30.67 (8.71) 29.50 (6.21) .58 
Male/Female, n 9/30 3/5 .69 
MÅDRS Score 28.82 (6.08) 25.62 (5.34) < .001 
YMRS Score† NA 2.33 (3.0) NA 
HCL Score 18.10 (5.39) 26.75 (3.01) .01 
Illness Duration, years 9.39 (7.96) 9.75 (5.44) .88 
Age of onset, years 21.28 (8.63) 19.75 (3.45) .41 
Number of mood episodes 2 (3) 5 (9.5) .009 
Years of education 14.78 (2.70) 15.43 (3.60) .058 
Full time employment, % 50 35 0.02 
Comorbid Diagnoses, n 
GAD=9; SAD=5, 
OCD=4; PD=2 
PTSD=2 
None NA 
 
Table 1: Sample characteristics. Values are reported as mean (SD) except where indicated otherwise. 
Number of episodes are reported as median (interquartile range).  MÅDRS: Montgomery-Åsberg 
Depression Rating Scale, YMRS: Young Mania Rating Scale, GAD: Generalized Anxiety Disorder, 
SAD: Social Anxiety Disorder, OCD: Obsessive Compulsive Disorder, PD: Panic Disorder, PTSD: Post-
Traumatic Stress Disorder, BP-I: Bipolar Disorder Type I, BP-II: Bipolar Disorder Type II. †YMRS scores 
were recorded only for bipolar disorder subjects. 
 
Results 
Forty-seven currently depressed patients were recruited. Subjects were diagnosed with either 
unipolar depression or bipolar disorder (type I or II), and no subjects met criteria for bipolar 
disorder-not otherwise specified. The study was conducted between December 2013 and 
June 2016. Fifty-one patients that expressed an interest in participating in the study (see Wise 
et al., 2016 for details) gave consent and were enrolled into the study. Of these 2 did not 
complete the study (one participant did not complete the MRI scan while one withdrew 
consent). Two subjects were excluded from these analyses due to missing questionnaire data. 
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Demographic and clinical details for both groups are shown in Table 1. No subjects reported 
a history of psychotic illness outside the context of manic episodes. There were no significant 
clinical differences in participant characteristics between the two scanners used (HCL scores: 
t = 0.04, p = 0.97, MÅDRS scores: t = 0.11, p = 0.91). Age was not correlated with grey matter 
volume within our regions of interest, as assessed by univariate regression (no clusters with 
p > .05 FDR corrected). 
 
Grey matter volume and symptom severity  
Predictive accuracies are shown in Figure 1. We were able to predict depression severity with 
a mean squared error of 30.59 (mean absolute error = 4.38, Figure 2), which was shown to 
be significant using permutation tests (p = 0.006, permutation test). When examining feature 
weights from the support vector regression, the highest weights were observed in the bilateral 
insula, suggesting that grey matter volume in this region is most strongly predictive of symptom 
severity. The direction of these weights was particularly consistent in the anterior part of the 
insula (Figure 2). Support vector regression analysis was able to predict individual hypomania 
scores with a mean-squared error of 35.50 (mean absolute error = -4.36), which did not survive 
permutation testing (p = 0.18). Univariate analyses did not detect any clusters exhibiting 
significant correlations with HCL scores or MÅDRS scores.  
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Figure 1: Relationship between true MÅDRS values and values predicted by the model. MÅDRS: 
Montgomery-Åsberg Depression Rating Scale. 
 
Relationship between symptoms and predictive accuracy 
In order to confirm the specificity of predictive accuracy to the symptoms in question, we 
investigated whether the volume in the regions associated with depression predicted 
hypomanic symptoms and vice versa. As expected, volume in regions thought to be 
associated with depression did not predict hypomanic symptoms (p = .22, mean squared error 
= 35.48, mean absolute error = 4.29), and volume in regions thought to be associated with 
hypomania did not predict depressive symptoms (p = .67, mean squared error = 35.70, mean 
absolute error = 4.41).  
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Figure 2: Support vector regression weights, focusing on the bilateral insula. Positive weights indicate 
that greater grey volume predicts higher MÅDRS scores, while negative weights predict the inverse. 
MÅDRS: Montgomery-Åsberg Depression Rating Scale. 
 
 
Figure 3: Distributions of outcome measures. HCL: Hypomania Checklist, MÅDRS = Montgomery 
Åsberg Depression Rating Scale.  
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Relationship between demographic and clinical variables 
We also explored relationships between demographic and clinical variables and HCL scores 
that could potentially affect the interpretation of our results. There was no significant 
correlation between age and HCL scores (r(45) = -.02, p = .83) or MÅDRS scores (r(45) = -
.05, p = .64), and there was no significant difference between males and females in HCL 
scores (t(45) = 1.59, p = .12, d = 0.40) or MÅDRS scores (t(45) = 0.88, p = .38, d = 0.22). 
There was also no significant correlation between illness duration and HCL scores (r(45) = -
.19, p = .20) or MÅDRS scores (r(45) = .13, p = .39), or between the number of mood episodes 
experienced and HCL (ρ(45) = 0.12, p = 0.42) or MÅDRS (ρ(45) = 0.04, 0.79). HCL scores 
and MÅDRS scores were positively correlated (r(45) = .47, p < .001). To ensure that our results 
were not influenced by confounding effects of comorbidities in some subjects, we compared 
symptom severity scores between subjects with and without comorbidity. This demonstrated 
no significant differences for either MÅDRS (t(17.36) = 0.39, p = 0.70) or HCL (t(18.12) = 1.68, 
p = 0.11) scores. 
 
Differences between scanners 
As our sample were scanned on two identical scanners, we also sought to determine any 
potential influence of using two physical locations on our results. As it is not possible to include 
such covariates in the support vector regression, we used a support vector machine cluster to 
examine differences in patterns of grey matter volume between scanners, using grey matter 
volume in our regions of interest to predict which scanner the subject was scanned on. This 
classification was significant in the regions we hypothesised to be related to bipolarity (p = 
0.023, permutation test) but not in the regions we showed to predict depressive symptom 
severity (p = 0.10, permutation test) suggesting that patterns of grey matter volume are unlikely 
to be the source of our positive results, but may have influenced our analysis of hypomanic 
symptom severity and could potentially explain the negative result here. 
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Discussion 
In this study, we investigated whether patterns of grey matter loss in the prefrontal cortex and 
bilateral insula found in our meta-analysis in both unipolar and bipolar disorders represent 
specific substrates of depressive symptoms. We also evaluated the significance of self-
reported bipolar symptoms in differentiating grey matter loss in in the left hippocampus, right 
middle temporal gyrus and right dorsolateral prefrontal cortex. We showed that volume in 
regions previously shown to be commonly reduced in unipolar and bipolar disorders predicts 
depressive symptom severity, suggesting for the first time that volumetric alteration in these 
regions might represent a substrate of depressive symptoms across both affective disorders. 
In contrast, we found no reliable evidence that volume in regions shown to be differentially 
affected in unipolar and bipolar disorders were associated with self-reported measures of 
mood elevation. 
The most highly weighted voxels in the prediction of depressive symptoms were located in the 
insula bilaterally. However, these weights ranged from positive to negative, indicating that a 
pattern of both elevated and reduced grey matter volume in the insula predicts depressive 
symptom severity. Strongest negative weights were present in the anterior and ventral portions 
of our insula regions of interests, whereas positive weights were observed in the posterior 
section. Other regions included in our model, such as the medial prefrontal cortex, had 
relatively weak weights, although this does not imply that they did not contribute to accurate 
prediction. The insula is known to play a crucial role in awareness of bodily states, and its role 
in depressive symptomatology may relate to aberrant interoceptive processing (28–30). The 
whole insula has recently been shown to be reduced in volume across other psychiatric 
disorders (12), suggesting the importance of evaluating grey matter volume sub-fields in future 
studies in the context of structural and functional networks to improve diagnostic specificity.  
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Our results show that a specific pattern of grey matter volume alteration, particularly in the 
insula, predicts depressive symptom severity, providing evidence for state effects in this 
specific sub-field. Notably, activity in this region has also been shown to predict response to 
both psychological and pharmacological treatments in depression (31), and our results provide 
further evidence of its association with depression symptomatology. Interestingly, predictive 
weights in the medial prefrontal cortex were low, suggesting that grey matter volume in this 
region is not related to current symptom severity. A potential explanation for this is that 
volumetric reductions in this region are in fact a result of life stress rather than depression per 
se (32).  
Interestingly, we observed a gradient of negative to positive weights from the anterior to 
posterior sections of the insula. The anterior insula is known to play a key role in emotional 
awareness, in conjunction with prefrontal regions to which it is connected, while the posterior 
anterior functions as a low-level primary interoceptive sensory area, creating a gradient from 
simple representations of bodily states to a complex representation of emotional states. 
Speculatively, our results may reflect a shift from bottom-up to top-down processing of sensory 
information about bodily states in depression, however this proposal would require direct 
testing. It is also interesting to observe positive weights, suggesting increased volume 
associated with higher symptom severity, in this region as this contradicts previous work 
showing reduced volume in this region in patients versus controls (7). This may indicate that 
differences shown between patients do not necessarily reflect symptom severity; it is possible 
that while individuals with depression exhibit reduced grey matter volume on average relative 
to healthy individuals, volume within this group correlates positively with symptom severity. 
These findings add to previous work investigating relationships between brain volume and 
depressive symptoms. Recent work examining subcortical volume and cortical thickness has 
failed to find any correlation with symptom severity (33,34), which raises concerns over the 
specificity of volumetric alterations to depression, especially in the context of research showing 
that volumetric alteration in several regions appears to be present across disorders (12). 
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However, these approaches are unable to account for spatially distributed patterns of 
volumetric change, unlike the multivariate methods employed here. Our results provide 
evidence that volumetric changes observed in case-control comparisons within unipolar and 
bipolar depression are indeed associated with symptoms of depression, suggesting that these 
do not represent a putative general factor underlying all psychopathology (12). 
Our null results in relation to the prediction of bipolarity add to the only previous study which 
used functional MRI to show that variation in neural systems responsible for affective 
generation and regulation may be affected by the presence of bipolar symptoms within 
depressive disorders (35). This might indicate that self-rated symptoms might not be the most 
effective way to identify morphometric changes in our network, that neuropathology of 
bipolarity might be best characterised by functional networks or perhaps that the regions that 
distinguished unipolar and bipolar disorders in our previous meta-analysis are not sufficiently 
generalizable across samples. Having recruited currently depressed participants, results 
might also suggest a possible fluctuation in morphometric changes influenced by mood state 
at the time of scanning. However, it is important to note that our sample had relatively low 
hypomania scores due to the small number of severe bipolar cases (i.e. bipolar type I), which 
is likely to have limited our ability to detect such relationships, and as such this result should 
be interpreted with caution. Including larger numbers of bipolar type I subjects who have 
experienced more substantial mood elevation in the past could allow future studies to shed 
light on this issue. Future studies could also consider including a sample of individuals with 
bipolar disorder scanned in a hypomanic state to better discriminate the significance of mood 
state in the definition of this brain network in relation to objective rating scales such as the 
Young Mania Rating Scale. 
This study has a number of strengths. Firstly, our sample consisted entirely of individuals free 
from psychotropic medication. Medications used to treat affective disorders can have effects 
on grey matter volume (36,37), and our medication-free sample limits the likelihood that such 
effects are responsible for the results. We excluded individuals who met criteria for 
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substance/alcohol misuse or dependence. We also corroborated clinical diagnoses by 
reviewing medical notes and by gathering available collateral information to exclude axis II 
comorbidity as far as possible. Additionally, despite our sample being scanned on two 
scanners, we showed no difference in patterns of grey matter volume between scanners in 
the regions driving our prediction of depressive symptom severity suggesting that this was 
unlikely to be driving these results. However, we did find differences between scanners in 
regions hypothesised to be associated with hypomanic symptom severity, and it is possible 
that this issue may have limited our ability to detect relationships with symptom severity in 
these areas. 
Another important strength of this study is our use of a machine learning method that offers a 
number of advantages over traditional univariate voxel-based analysis, including the ability to 
account for distributed patterns of variation in grey matter volume and to predict bipolarity on 
an individual basis. As a result, the null results observed in our univariate analyses are likely 
due to the inability of traditional univariate statistics to identify more complex patterns of grey 
matter volume variation that predict depressive symptom severity. Notably, this pattern of 
results implies that the relationship between grey matter volume and symptom severity in 
these regions is a complex one.   
However, it should be noted that this study does have a number of limitations. Firstly, we 
chose to base our feature section for the analysis examining depressive symptoms on regions 
shown in our previous work to identify unipolar and bipolar disorders. Hence, it is possible that 
although we were able to confirm morphometric changes in this network, there may be other 
regions that do accurately predict symptoms. It is difficult to perform data-driven feature 
selection with the sample size used here, as defining features on the same data that is used 
to test predictive accuracy inevitably biases the success of the analysis due to the circular 
nature of this procedure. In view of this concern, we chose to use a truly independently defined 
set of features to avoid an inflated false positive rate. Studies using larger samples would be 
beneficial to enable data-driven feature selection on independent subsets of available data. 
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Additionally, it is important to note that our sample size was relatively modest, and this may 
have limited our ability to detect significant predictive regions of volumetric variation. Future 
research in larger samples may be more successful in this respect. However it is unlikely that 
this would have led to higher accuracy than detected in cross validation, which typically tends 
to show exaggerated accuracy (38). Furthermore, although we included patients with a wide 
range of hypomanic symptoms to represent the entire bipolar severity spectrum, including 
those diagnosed with bipolar I/II disorder, few patients had experienced manic episodes and 
our sample was dominated by individuals with unipolar depression. Un-medicated individuals 
with bipolar depression experiencing a depressive episode are challenging to recruit, making 
this a difficult task (17). We were however also interested in predicting levels of depressive 
symptoms and bipolarity in individuals presenting with a major depressive episode in view of 
the well-described existence of sub-threshold hypomanic symptoms in subjects presenting 
with symptoms of depression. In this group, not uncommonly individuals report features 
consistent with unipolar depression at the time of clinical contact but are likely characterised 
by a bipolar diathesis, have an increased chance of presenting as bipolar disorder at some 
point during the natural history of their condition, and respond less favourably to 
antidepressant treatment. As a result our coverage of the full bipolar spectrum could be 
improved, and it would be helpful to include subjects with a history of severe manic episodes 
and subgroups in different mood states. We also recruited relatively few subjects with very low 
scores on the HCL, and it may be that the few subjects reporting low scores on the HCL limited 
the training success of the model at the low end of the spectrum.  
It should also be noted that we carefully recorded medication free status in our inclusion 
criteria. Detailed historical information could not be obtained however beyond the criteria set 
for inclusion and at least theoretically, medication exposure including lifetime exposure could 
have influenced our results. Other limitations included the presence of comorbidities in some 
of the depressed patients although comparing symptom severity scores between subjects with 
and without comorbidity did not change the results. 
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Finally, measuring historic bipolar symptoms with self-report measures is open to reporting 
and recall biases. In the absence of direct observation of psychopathology, the HCL remains 
nevertheless one of the most reliable self-report or clinician-rated measures for historic 
symptoms of bipolarity (13). Importantly, a high score on the HCL does not necessarily indicate 
a diagnosis of bipolar disorder and it was not our intention to use the HCL as a diagnostic tool. 
Overall, the HCL has been shown to be sensitive to low-level hypomanic symptoms and to be 
a clinically meaningful dimension within unipolar depression (39–41). Although it was not our 
primary aim, our results indicate that further research is warranted to evaluate the clinical 
relevance of the predictive value of high HCL scores at brain level in longitudinal studies. In 
this context, repeated clinical assessments would be highly valuable not only to confirm 
affective diagnoses but also reduce potential contamination from axis II disorders which are 
difficult to fully exclude in studies with a cross sectional design.   
Results from this report suggest that structural alterations in the brain are associated with 
depressive but not bipolar symptoms. Further research could validate this model by assessing 
its specificity to current depressive symptoms. For example, if the model is truly predicting 
current depressive symptom severity rather than a cumulative effect of lifetime depressive 
episodes, it should predict low levels of symptoms in remitted patient groups. Additionally, it 
is likely that there are other systems that may play a role in both depressive and hypomanic 
symptoms. There is therefore a clear need for further research into other aspects of other 
neurobiological parameters that may be associated with depression bipolarity, such as 
inflammation (42), stress (43), and fast acting neurotransmission (44). Finally, the degree to 
which such biological parameters can provide prognostic value in terms of stratifying treatment 
choice and clinical response is an area for future trials. 
In conclusion, in this work we identified a pattern of volumetric change that predicted 
depressive symptom severity across unipolar and bipolar disorders, but were unable to do so 
for hypomanic symptom severity. This suggests that depressive symptoms are associated 
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with a specific pattern of grey matter volume alteration, but that further work is required to 
validate the neurobiological relationship with these symptoms. 
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